Faiza Zafar
About
Faiza Zafar is a scholar working on Hematology, Molecular Biology and Oncology.
According to data from OpenAlex, Faiza Zafar has authored 40 papers receiving a total of 507 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Hematology, 24 papers in Molecular Biology and 24 papers in Oncology. Recurrent topics in Faiza Zafar's work include Multiple Myeloma Research and Treatments (37 papers), Cancer Treatment and Pharmacology (19 papers) and Protein Degradation and Inhibitors (16 papers). Faiza Zafar is often cited by papers focused on Multiple Myeloma Research and Treatments (37 papers), Cancer Treatment and Pharmacology (19 papers) and Protein Degradation and Inhibitors (16 papers). Faiza Zafar collaborates with scholars based in United States, Canada and United Kingdom. Faiza Zafar's co-authors include Roger Pearse, Rubén Niesvizky, Morton Coleman, David Jayabalan, Tomer M. Mark, Paul J. Christos, Selina Chen‐Kiang, John P. Leonard, Karen Pekle and Scott Ely and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
In The Last Decade
Faiza Zafar
36 papers receiving 496 citations
Peers
Faiza Zafar
Christy Samaras United States
Michelle E. Maglio United States
Maria Gavino United States
Angelo Belotti Italy
Anna Hockaday United Kingdom
Nuriet K. Khuageva Russia
Thomas G Martin United States
Ioannis Panagiotidis Greece
Maria Grishunina Russia
A. V. Shubina Russia
Citations per year, relative to Faiza Zafar Faiza Zafar (= 1×)
peers
Christy Samaras
Countries citing papers authored by Faiza Zafar
Since
Specialization
Citations
This map shows the geographic impact of Faiza Zafar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Faiza Zafar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Faiza Zafar more than expected).
Fields of papers citing papers by Faiza Zafar
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Faiza Zafar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Faiza Zafar. The network helps show where Faiza Zafar may publish in the future.
Co-authorship network of co-authors of Faiza Zafar
This figure shows the co-authorship network connecting the top 25 collaborators of Faiza Zafar. A scholar is included among the top collaborators of Faiza Zafar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Faiza Zafar. Faiza Zafar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Aslam, Muhammad Luqman, et al.. (2025). GREEN APPROACH TO PHYTOCHEMICALS: ALKALOIDS PURIFICATION AS USED IN HEALTH THERAPEUTICAL AND WELLNESS ACTIVITIES. 3(3 (Health & Rehab)). 201–209.
2.
Johnson, Travis S., Parvathi Sudha, Vivek S. Chopra, et al.. (2025). Utilizing genomics to identify novel immunotherapeutic targets in multiple myeloma high-risk subgroups. Genome Medicine. 17(1). 79–79.
3.
Zafar, Faiza, et al.. (2024). Effects of Socioeconomic Status and Healthcare Resource Availability on Survival in Older (≥66 years) Non-Hispanic Black Patients Versus Non-Hispanic White Patients With Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 25(4). 285–292.e1.
4.
Jagannath, Sundar, Yi Lin, Hartmut Goldschmidt, et al.. (2020). KarMMa-RW: A study of real-world treatment patterns in heavily pretreated patients with relapsed and refractory multiple myeloma (RRMM) and comparison of outcomes to KarMMa.. Journal of Clinical Oncology. 38(15_suppl). 8525–8525.
5.
Zafar, Faiza, et al.. (2019). Study of Analgesic Activity of Methanolic Extracts of Cuminum Cyminum (L.) and Centratherum Anthelminticum (L.) in Mice. SHILAP Revista de lepidopterología. 24(2). 90–95.
6.
Rifkin, Robert M., Sundar Jagannath, Brian G.M. Durie, et al.. (2018). Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry. Clinical Therapeutics. 40(7). 1193–1202.e1.
7.
Siegel, David S., Gary J. Schiller, Christy Samaras, et al.. (2018). Pomalidomide + Low-Dose Dexamethasone + Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure. Blood. 132(Supplement 1). 3271–3271.
8.
Tay, Jason, Ravi Vij, Maxim Norkin, et al.. (2018). Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scales. Leukemia & lymphoma. 60(5). 1275–1282.
9.
Siegel, David S., Gary J. Schiller, Christy Samaras, et al.. (2018). Pomalidomide (POM) + low-dose dexamethasone (LoDEX) + daratumumab (DARA) in relapsed and/or refractory multiple myeloma (RRMM) after lenalidomide (LEN)-based treatment (Tx) failure.. Journal of Clinical Oncology. 36(15_suppl). 8027–8027.
10.
Siegel, David, Gary J. Schiller, Kevin Song, et al.. (2017). Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) Safety and Efficacy in Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Previously Treated with a Proteasome Inhibitor (PI) and in Whom Last Prior Therapy with Lenalidomide (LEN) Failed. Blood. 130. 1812–1812.
11.
Shah, Jatin J., Rafat Abonour, Christina Gasparetto, et al.. (2017). Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes. Clinical Lymphoma Myeloma & Leukemia. 17(9). 575–583.e2.
12.
Jagannath, Sundar, Rafat Abonour, Brian G.M. Durie, et al.. (2017). Impact of post-autologous stem cell transplant (ASCT) maintenance therapy on outcomes in patients (Pts) with newly diagnosed multiple myeloma (NDMM) using the large prospective community-based Connect MM registry.. Journal of Clinical Oncology. 35(15_suppl). 8040–8040.
13.
Rifkin, Robert M., Rafat Abonour, Brian G.M. Durie, et al.. (2016). Treatment Patterns from 2009 to 2015 in Patients with Newly Diagnosed Multiple Myeloma in the United States: A Report from the Connect® MM Registry. Blood. 128(22). 4489–4489.
14.
Mark, Tomer M., I. Alex Bowman, Adriana Rossi, et al.. (2014). Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma. Leukemia & lymphoma. 55(12). 2842–2849.
15.
Niesvizky, Rubén, Tomer M. Mark, Maureen Ward, et al.. (2013). Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization. Clinical Cancer Research. 19(6). 1534–1546.
16.
Zafar, Faiza, et al.. (2010). An evaluation of the role of bone marrow biopsy in patients with multiple myeloma who achieve an unconfirmed stringent complete remission.. Journal of Clinical Oncology. 28(15_suppl). 8144–8144.
17.
Mark, Tomer M., Jessica Stern, Jessica Furst, et al.. (2008). Stem Cell Mobilization with Cyclophosphamide Overcomes the Suppressive Effect of Lenalidomide Therapy on Stem Cell Collection in Multiple Myeloma. Biology of Blood and Marrow Transplantation. 14(7). 795–798.
18.
Niesvizky, Rubén, Tara Naib, Paul J. Christos, et al.. (2007). Lenalidomide‐induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment‐naïve patients undergoing front‐line lenalidomide and dexamethasone therapy. British Journal of Haematology. 138(5). 640–643.
19.
Niesvizky, Rubén, Déborah Martı́nez-Baños, Jessica Jalbrzikowski, et al.. (2007). Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leukemia & lymphoma. 48(12). 2330–2337.
20.
Niesvizky, Rubén, Scott Ely, Maurizio DiLiberto, et al.. (2005). Multicenter Phase II Trial of the Histone Deacetylase Inhibitor Depsipeptide (FK228) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM).. Blood. 106(11). 2574–2574.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Christy Samaras Breakdown of academic impact, for papers by Michelle E. Maglio Breakdown of academic impact, for papers by Maria Gavino Breakdown of academic impact, for papers by Angelo Belotti Breakdown of academic impact, for papers by Anna Hockaday Breakdown of academic impact, for papers by Nuriet K. Khuageva Breakdown of academic impact, for papers by Thomas G Martin Breakdown of academic impact, for papers by Ioannis Panagiotidis Breakdown of academic impact, for papers by Maria Grishunina Breakdown of academic impact, for papers by A. V. Shubina